Non-Hodgkin's B-cell Lymphoma Clinical Trial
Official title:
A Phase 1 Study Evaluating Safety and Efficacy of EXP039 Treatment in Subjects With Relapsed and/or Refractory NHL
This is a single-center, non-randomized study to evaluate the safety and efficacy of EXP039 in relapsed and/or refractory NHL patients.
The study will include the following sequential phases: Screening, Apheresis, Baseline, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), EXP039 infusion and Follow-up Visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04317885 -
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04696432 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT02361346 -
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04693676 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Suspended |
NCT04148742 -
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03000192 -
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
|
||
| No longer available |
NCT02715843 -
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
|